The US Food and Drug Administration found no increased risk of suicidal behavior or ideation linked to popular weight-loss ...

The request comes after a two-year review into reported links between GLP-1RAs and psychiatric adverse events.

Agency officials say a comprehensive review “found no increased risk” related to suicide among users of the GLP-1 drugs used ...

The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential risk of suicidal thoughts from ...

Hormone therapy helps women. Now the FDA is reversing its warning on estrogen treatment which could change treatemtn for ...

The removal request is based on a ‘comprehensive review of available data’ that showed no increased risk of suicidal ideation and behavior.

The FDA is requesting that manufacturers of three GLP-1 receptor agonists remove information on risk for suicidal ideation ...

Hormone-based drugs used to treat hot flashes and other menopause symptoms will no longer carry a bold warning label about stroke, heart attack, dementia and other serious risks, the Food and Drug ...

The FDA is weighing a change that could make warning labels on dietary supplements appear less often on packaging.

The FDA approved a new safety warning for Depo-Provera alerting patients to a possible risk for a type of brain tumor called ...